DR info

Clinical trials : 23 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 106

Drugs and their primary sponsors and trial info

APD334
   Arena Pharmaceuticals
      2017   Phase 2   NCT03072953   Australia;New Zealand;
Adalimumab
   AbbVie
      2017   Phase 3   NCT03311464   Japan;
   Wake Forest University Health Sciences
      2007   Phase 2   NCT00690846   United States;
Anti-(complement C5a) IgG4 chimeric monoclonal antibody
   InflaRx GmbH
      2020   Phase 2   EUCTR2020-003273-21-PL   Poland;United States;
Baricitinib
   Oregon Health and Science University
      2021   Phase 2   NCT04901325   United States;
Canakinumab
   University of Zurich
      2011   Phase 2   NCT01302795   Switzerland;
Cosentyx®
   Technische Universität München, School of Medicine, represented by Dean
      2015   Phase 2;Phase 3   EUCTR2015-000762-65-DE   Germany;
Dehydrated human amnion/chorion membrane
   Louisiana State University Health Sciences Center in New Orleans
      2021   Phase 4   NCT05120726   United States;
EU/1/14/980/002
   Technische Universität München, School of Medicine, represented by Dean
      2015   Phase 2;Phase 3   EUCTR2015-000762-65-DE   Germany;
EU/1/14/980/003
   Technische Universität München, School of Medicine, represented by Dean
      2015   Phase 2;Phase 3   EUCTR2015-000762-65-DE   Germany;
Gevokizumab
   MedDerm Associates
      2015   Phase 3   NCT02366260   United States;
   XOMA (US) LLC
      2014   Phase 3   NCT02318914   Australia;Canada;United States;
      2013   Phase 2   NCT01882504   United States;
Gevokizumab open-label
   XOMA (US) LLC
      2014   Phase 3   NCT02326740   Australia;Canada;United States;
      2014   Phase 3   NCT02315417   United States;
Humira
   Wright State University
      2009   Phase 2   NCT00730717   United States;
IFX-1
   InflaRx GmbH
      2020   Phase 2   EUCTR2020-003273-21-PL   Poland;United States;
      2019   Phase 2   NCT03971643   Canada;Poland;United States;
Infliximab
   University Hospitals Cleveland Medical Center
      2008   -   NCT00791557   United States;
Ixekizumab
   Ohio State University
      2017   Phase 2   NCT03137160   United States;
Monoclonal antibody (Mab) sB24M
   SWISS BIOPHARMA MED GmbH
      2021   Early Phase 1   NCT04895566   Belarus;Latvia;
Neoral Oral Solution
   Nottingham University Hospitals NHS Trust
      2010   -   EUCTR2008-008291-14-IE   Ireland;United Kingdom;
      2009   Phase 4   EUCTR2008-008291-14-GB   Ireland;United Kingdom;
Neoral soft gelatin capsules
   Nottingham University Hospitals NHS Trust
      2010   -   EUCTR2008-008291-14-IE   Ireland;United Kingdom;
      2009   Phase 4   EUCTR2008-008291-14-GB   Ireland;United Kingdom;
Secukinumab
   Technische Universität München
      2016   Phase 1/Phase 2   NCT02733094   Germany;
Secukinumab 150 mg (2 injections per dose
   Wake Forest University Health Sciences
      2021   Phase 2   NCT04274166   United States;
Stelara
   University Hospital Tübingen
      2012   -   EUCTR2011-002920-41-DE   Germany;
Xilonix
   Janssen Research & Development, LLC
      2014   Phase 2   NCT01965613   United States;